Raptor Pharmaceutical Licenses Intellectual Property Related to Malaria From McGill University – MarketWatch

Dr. Philippe Gros, Professor of Biochemistry at McGill, said, “The challenge for researchers developing malaria treatments has been the ongoing evolution of drug-resistant parasites that necessitate the search for new drug formulations. We were encouraged by the preclinical results so far that cysteamine and related compounds may serve to improve the effectiveness of artemisinin when the two compounds are used in combination.”

Dr. Patrice Rioux, Raptor’s Chief Medical Officer said, “The research done at McGill has indicated that cysteamine may have clinical utility in malaria. As malaria remains a difficult to treat disease, we feel this is an appropriate and exciting therapeutic area to extend our studies of cysteamine bitartrate. We look forward to a continued collaboration with the researchers at McGill, as well as other malaria clinical thought leaders, as we take the program forward.”

via Raptor Pharmaceutical Licenses Intellectual Property Related to Malaria From McGill University – MarketWatch.

Advertisements


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s